Apogee Therapeutics (NASDAQ:APGE – Get Free Report) and DBV Technologies (NASDAQ:DBVT – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.
Earnings & Valuation
This table compares Apogee Therapeutics and DBV Technologies”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Apogee Therapeutics | N/A | N/A | -$83.99 million | ($2.42) | -20.28 |
| DBV Technologies | $15.73 million | 4.57 | -$72.73 million | ($4.50) | -0.78 |
DBV Technologies has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Apogee Therapeutics | 0 | 0 | 8 | 0 | 3.00 |
| DBV Technologies | 0 | 0 | 2 | 0 | 3.00 |
Apogee Therapeutics presently has a consensus target price of $83.88, suggesting a potential upside of 70.93%. DBV Technologies has a consensus target price of $30.00, suggesting a potential upside of 759.11%. Given DBV Technologies’ higher probable upside, analysts clearly believe DBV Technologies is more favorable than Apogee Therapeutics.
Insider and Institutional Ownership
79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 36.1% of Apogee Therapeutics shares are owned by company insiders. Comparatively, 1.9% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Apogee Therapeutics has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.
Profitability
This table compares Apogee Therapeutics and DBV Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Apogee Therapeutics | N/A | -21.81% | -20.94% |
| DBV Technologies | -815.73% | -106.07% | -76.17% |
Summary
Apogee Therapeutics beats DBV Technologies on 8 of the 12 factors compared between the two stocks.
About Apogee Therapeutics
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
